The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Early & Long-Term Remission of Spondyloarthritis

Early & Long-Term Remission of Spondyloarthritis

July 16, 2021 • By Jason Liebowitz, MD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

EULAR 2021—Rheumatologists and patients can reasonably ask: Is there a way to achieve sustained clinical remission in spondyloarthritis (SpA)? After all, a major goal of rheumatologic care is to return patients to the approximate levels of function and symptom-free existence they had prior to disease onset.

You Might Also Like
  • EULAR 2015: Emerging Concepts, Treatments for Axial Spondyloarthritis
  • Treating Early-Stage Spondyloarthritis May Prevent Disease Progression, Say Researchers at the ACR/ARHP Winter Rheumatology Symposium
  • Management of Psoriatic Arthritis, Treatment of Axial Spondyloarthritis Addressed at EULAR 2016
Explore This Issue
August 2021
Also By This Author
  • Researchers Seek the Best Methods to Maintain Remission in Vasculitis

At EULAR 2021, Filip Van den Bosch, MD, head of clinic and associate professor of rheumatology in the Department of Rheumatology at Ghent University Hospital, Belgium, spoke on the topic of disease inactivity in patients with SpA. In the process, he imparted many clinical pearls regarding how to care for these patients.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Dr. Van den Bosch posed an interesting question at the start of the lecture: How does one define remission in a heterogeneous disease, such as SpA? One potential answer: Clinical remission or inactive disease is the absence of clinical and laboratory evidence of significant inflammatory disease activity. When looking at clinical trials, this definition would mean using the most stringent measures of disease inactivity as measured by outcomes scores, such as the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), the Ankylosing Spondylitis Disease Activity Score (ASDAS) and the Disease Activity in PSoriatic Arthritis score (DAPSA).

However, in SpA, clinical evaluation of disease goes beyond just looking at axial and peripheral arthritis. Rheumatologists must also take into account such domains as enthesitis, dactylitis, psoriasis, inflammatory bowel disease and uveitis.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Treatment

Over the past 20 years, dermatologists have succeeded in frequently achieving complete remission of skin psoriasis in patients treated with biologics, such as those targeting the interleukin (IL) 12, IL-17 and IL-23 pathways, said Dr. Van den Bosch. However, in rheumatology, advances in biologic treatments have not shown the same degree of near complete success. This result may, in part, reflect the fact that the resolution of skin disease is a clear and consistent outcome that can be measured across patients. But evaluating disease activity in a multi-dimensional disease, such as SpA, is more challenging.

Part of the challenge may be the characteristics of patients enrolled in clinical trials and how these traits have changed over time. Vandendorpe et al. examined patient characteristics in 12 phase 2 and phase 3 trials conducted on the subject of psoriatic arthritis (PsA) in the era of biologic therapy. This study found several objective measures, such as average swollen and tender joint count and C-reactive protein levels, have decreased in study patient populations in recent years, whereas more subjective measures, such as patient assessment of pain and disease activity and Health Assessment Questionnaire-Disability Index (HAQ-DI) scores, have increased over time.1 Such changes in study populations may make it challenging to compare outcomes of patients in the present day to those of patients evaluated in studies 10 or 20 years ago.

Patient Care

Dr. Van den Bosch outlined several steps of his approach to caring for patients with SpA.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 3 | Single Page

Filed Under: Conditions, Meeting Reports, Spondyloarthritis Tagged With: AS Resource Center, EULAR, patient care, spondyloarthritisIssue: August 2021

You Might Also Like:
  • EULAR 2015: Emerging Concepts, Treatments for Axial Spondyloarthritis
  • Treating Early-Stage Spondyloarthritis May Prevent Disease Progression, Say Researchers at the ACR/ARHP Winter Rheumatology Symposium
  • Management of Psoriatic Arthritis, Treatment of Axial Spondyloarthritis Addressed at EULAR 2016
  • Adalimumab May Help Maintain Remission in Non-Radiographic Axial Spondyloarthritis

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)